Download Publications, in press, submitted 2001

Publications, 2002
Department of Oncology, Lund University Hospital, Lund
1.
Amini R-M, Glimelius B, Gustavsson A, Ekman T, Erlanson M, Haapaniemi E, and
Enblad G: A population-based study of the outcome for patients with first relapse of
Hodgkin´s lymphoma. Eur J Haematol 2002; 68:225-232.
2.
Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall-Nittby L,
Pettersson-Sköld D, Sverrisdottir A, Söderberg M, Klaar S, and Bergh J: A populationbased study on the first forty-eight breast cancer patients receiving trastuzumab
(HerceptinR) on a named patient basis in Sweden. Acta Oncol 2002; 41 (3):276-281.
3.
Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Conati D,
Manfrini M, Lari S, Briccoli A, and Forni C: High dose Ifosfamide in combination with high
dose Methotrexate, Adriamycin and Cisplatin in the neoadjuvant treatment of extremity
osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma
Pilot Study. J Chemother 2002; 14(2):198-206.
4.
Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, Wennerberg J, and
Strand S-E. FDG PET studies during treatment: Prediction of therapy outcome in head
and neck squamous cell carcinoma. Head and Neck 2002; 24:127-135.
5.
Dreinhöfer K, Baldetorp B, Åkerman M, Fernö M, Rydholm A, and Gustafson P: DNA
ploidy in soft tissue sarcoma: Comparison of flow and image cytometry with clinical follow-up in 93 patients. Cytometry 2002; 50(1):19-24.
6.
Elit L, Pal T, Goshen R, Jernström H, Ackerman I, Fyles A, Carey M, Mitchell M, Aube J,
and Narod SA: Familial and hormonal risk factors for papillary serous uterine cancer.
Eur J Gynaec Oncol 2002; 3:187-190.
7.
Enblad G, Gustavsson A, Sundström C, and Glimelius B, for the Swedish Lymphoma
Study Group: Patients above sixty years of age with Hodgkin´s lymphoma treated with
a new strategy. Acta Oncol 2002; 41 (7/8):659-667.
8.
Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenter C, Martino R, Dekker AW,
Prentice HG, Gustavsson A, and Ljungman P: Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation
survey. Br J Hematol 2002; 117:444-450.
9.
Fernebro E, Dictor M, Bendahl P-O, Fernö M, and Nilbert M: Evaluation of the tissue
microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol
Lab Med 2002; 126:702-705.
10. Fernebro E, Halvarsson B, Baldetorp B, and Nilbert M: Predominance of CIN versus
MSI in the development of rectal cancer at young age. BMC Cancer 2002; 2:25:1-8.
11. Fredriksson I, Liljegren G, Arnesson L-G, Emdin SO, Palm-Sjövall M, Fornander T,
Holmqvist M, Holmberg L, and Frisell J: Consequences of axillary recurrence after conservative breast surgery. Br J Surgery 2002; 89:902-908.
12. Fredriksson I, Liljegren G, Arnesson L-G, Emdin SO, Palm-Sjövall M, Fornander T,
Holmqvist M, Holmberg L, and Frisell J: Local recurrence in the breast after conservative surgery – a study of prognosis and prognostic factors in 391 women. Eur J
Cancer 2002; 38(14): 1860-1870.
13. Gruvberger S, Ringnér M, Edén P, Borg Å, Fernö M, Peterson C, and Meltzer P: Expression profiling to predict outcome in breast cancer: the influence of sample selection.
Breast Cancer Res 2002; 5(1):23-26.
14. Hardell L, Eriksson M, and Nordström M: Exposure to pesticides as risk factor for NonHodgkin´s lymphoma and hairy cell leukemia: Pooled analysis of two Swedish casecontrol studies. Leukemia and Lymphoma 2002; 43(5): 1043-1049.
15. Hindorf C, Lindén O, Tennvall J, Wingårdh K, and Strand S-E: Time dependence of the
activity concentration ratio of red marrow to blood and implications for red marrow dosimetry. Cancer 2002; 94:1235-1239.
16. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Möller S,
Edvinsson L, and Erlinge D: UDP acts as a growth factor for vascular smooth muscle
cells by activation of P2Y(6) receptors. Am J Physiol Heart Circ Physiol 2002; 282
(2):784-792.
17. Höglund M, Gisselsson D, Hansen GB, Säll T, Mitelman F, and Nilbert M: Dissecting
karyotypic patterns in colorectal tumors: two distinct but overlapping pathways in the adenoma-carcinoma transition. Cancer Res 2002; 62:5939-5946.
18. Jerkeman M, Åman P, Cavallin-Ståhl E, Torlakovic E, Åkerman M, Mitelman F, and
Fioretos T: Prognostic implications of BCL6 rearrangemant in uniformly treated patients
with diffuse large B-cell lymphoma – a Nordic Lymphoma Group Study. Int J Oncol
2002; 20 (1):161-165.
19. Johansson T, Soto Thompson M, Stenberg M, af Klinteberg C, Andersson-Engels S,
Svanberg S, and Svanberg K: Feasibility study of a novel system for combined light dosimetry and interstitial photodynamic treatment of massive tumors. Applied Optics
2002; 41 (7):1462-1468.
20. Jönsson M, Dejmek J, Bendahl P-O, and Andersson T: Loss of wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 2002;
62(2):409-416.
21. Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, Guénel P,
Hardell L, Cyr D, Ballard T, Zambon P, Morales Suárez-Varela MM, Stang A, and Olsen
J: Occupational risk factors for small bowel carcinoid tumor: A European populationbased case-control study. J Occup Environ Med 2002; 44:516-522.
22. Kinhult S, Eskilsson J, Albertsson M, and Cwikiel M: Endothelial damage after treatment
with low-molecular weight heparins – a morphological study. Scand Cardiovasc J. In
press.
23. Koul A, Willén R, Bendahl P-O, Nilbert M, and Borg Å: Distinct sets of gene alterations in
endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002; 94:
2369-2379.
24. Koul A, Bendahl P-O, Borg Å, Fernö M, Lidebring MF, Högberg T, Einarsson EL., Ridderheim M, and Willén R: TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. Int J Gynecol Cancer 2002; 12:362-371.
25. Lindén O, Hindorf C, Tennvall J, Segren S, Wingårdh K, and Strand S-E: Single tumor
cell uptake and dosimetry of Technetium-99m Fab´anti-CD22 in low-grade B-cell lymphoma. Cancer 2002; 94/4:1270-1274.
2
26. Lindén O, Tennvall J, Hindorf C, Cavallin-Ståhl E, Lindner K-J, Ohlsson T, Wingårdh K,
and Strand S-E: 131l-labelled Anti-CD22 MAb (LL2) in patients with B-cell lymphomas failing chemotherapy. Treatment outcome, haematological toxicity and bone marrow absorbed dose estimates. Acta Oncol 2002; 41(3):297-303.
27. Lindén O: Radioimmunotherapy of B-cell lymphoma. Clinical studies with anti-CD22 antibodies. Lund University 2002. 06-07-2002 PhD. Dr in Medical Science.
28. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R,
Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM,
Magdalenat H, Brunner N, Duggan C, Lisboa BW, Bendahl P-O, Quillien W, Daver A,
Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broet P,
Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn
JG, O´Higgins N, Eppenberger U, Janicke F, Schmitt M, and Foekens JA: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in
8377 breast cancer patients. J Natl Cancer Inst 2002; 94(2):116-128.
29. Luoma M-L, Hakamies-Blomqvist L, Sjöström J, Mouridsen H, Pluzanska A, Malmström
P-O, Bengtsson N-O, Hultborn R, Östenstad B, Mjaaland I, Valvere V, Wist E, Baldursson G, Ahlgren J, and Blomqvist C. Physical performance, toxicity and quality of life as
assessed by the physician and the patient. Acta Oncol 2002; 41:44-49.
30. Mandahl N, Gustafson P, Mertens F, Åkerman M, Baldetorp B, Gisselsson D, Knuutila S,
Bauer HCF, and Larsson O: Cytogenetic abberations and their prognostic impact in
chondrosarcoma. Genes, Chromosomes & Cancer 2002; 33:188-200.
31. Narod S, Dubé M-P, Klijn J, Lubinski J, Lynch H, Ghadirian P, Provencher D, Heimdal K,
Moller P, Robson M, Offit K, Isaacs C, Weber B, Friedman E, Gershoni-Baruch R,
Rennert G, Pasini B, Wagner T, Daly M, Garber J, Neuhausen S, Ainsworth P, Olsson
H, Evans G, Osborne M, Couch F, Foulkes W, Warner E, Kim-Sing C, Olopade O, Tung
N, Saal H, Weitzel J, Merajver S, Gauthier-Villars M, Jernstrom H, Sun P, and Brunet
32. J-S: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation
carriers. J of the National Cancer Institute 2002; 94 (23):1773-1779.
33. Nilbert M, and Planck M: Mismatch-repair deficiency in the development of tumor types
associated with Hereditary Nonpolyposis Colorectal Cancer. Recent Research Developments in Cancer 2002; 4:395-418.
34. Nilbert M, and Coffin CM: Gardner syndrome. In: Pathology & Genetics; tumors of soft
tissue and bone. WHO 2002; 352-354.
35. Nilbert M, Grönberg H, and Lindblom A: Hereditary nonpolyposis colorectal cancer – an
update. Läkartidningen 2002; 34:3296-300.
36. Nordengren J, Fredstorp-Lidebring M, Bendahl P-O, Brunner N, Fernö M, Högberg T,
Stephen RW, Willén R, and Casslén B: High tumor tissue concentration of plasminogen
activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002; 97(3):379-385.
37. Olsson H, Bladstrom A. A cohort study of reproductive factors and family history of
breast cancer in southern Sweden. Breast Cancer Res Treat. 2002 Dec;76(3): 203-209.
38. Wirfalt E, Mattisson I, Gullberg B, Johansson U, Olsson H, Berglund G.Postmenopausal
breast cancer is associated with high intakes of omega6 fatty acids (Sweden). Cancer
Causes Control. 2002 Dec; 13(10): 883-893
3
39. Planck M, Halvarsson B, Pålsson E, Hallén M, Ekelund M, Pålsson B, Baldetorp B, and
Nilbert M: Cytogenetic aberrations and heterogeneity of mutations in repeat-containing
genes in an HNPCC colon carcinoma. Cancer Genet and Cytogenet 2002; 134:46-54.
40. Planck M, Rambech E, Möslein Gm, Muller W, Olsson H, and Nilbert M: High frequency
of microsatellite instability and loss of mismatch-repair protein expression in double primary cancers of the endometrium and colorectum. Cancer 2002; 94:2502-2510.
41. Relander T, Karlsson S, and Richter J: Oncoretroviral gene transfer to NOD/SCID repopulating cells using three different viral envelopes. J Gene Med 2002; 4:122-132.
42. Relander T, Brun A, Olsson K, Pedersen L, and Richter J: Overexpression of gibbon ape
leukemia virus (GALV) receptor (GLVR1) on human CD34+ cells increases gene transfer mediated by GALV pseudotyped vectors. Molecul Therapy 2002; 6(3):400-406.
43. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, and Parö G:
Randomized trial of single agent paclitaxel given weekly versus every three weeks and
with peroral versus intravenous steroid premedication to patients with ovarian cancer
previously treated with platinum. Acta Oncol 2002; 41(5):418-424.
44. Lao H. Saal, Carl Troein, Johan Vallon-Christersson, Sofia Gruvberger, Åke Borg and
Carsten Peterson. BioArray Software Environment: A Platform for Comprehensive Management and Analysis of Microarray Data. Genome Biology 2002 3(8): software0003.10003.6
45. Sjöström J, Collan J, Boguslawski K, Franssila K, Bengtsson N-O, Mjaaland I, Malmström P, Östenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, and
Blomqvist C: C-erbB-2 expression does not predict response to docetaxel or sequential
methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002; 38:535542.
46. Sjöström J, Blomqvist C, Boguslawski K, Bengtsson N-O, Mjaaland I, Malmström P,
Ostenstadt B, Wist E, Valvere V, Takayama S, Reed J,and Saksela E: The predictive
value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced
breast cancer. Clin Cancer Res 2002; 8:811-816.
47. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Åkerman M, Hjelm Skog
AL, and Wallin G: Anaplastic thyroid carcinoma: three protocols combining doxorubicin,
hyperfractionated radiotherapy and surgery. Br J Cancer 2002; 86:1848-1853.
48. Tennvall J, Carlsson J, Lundqvist H, Stigbrand T, och Strand S-E: Radioimmunoterapi av
maligna tumörer. Sv Medicin 2002; 72:105-124.
49. Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P,
Østenstad B, Wist E, Valvere V, Saksela E, Paavonen T, and Blomqvist C: Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J
Cancer 2002; 86:1905-1908.
50. Wang Zh, Garkavij M, Tennvall J, and et al: Application of extracorporeal immunoadsorption (ECAT) to reduce circulating blood radioactivity after intraperitoneal administration of 111In-HMFG1-biotin. Cancer 2002; 94:1287-1292.
51. Åkervall J, Borg Å, Dictor M, Jin C, Jin Y, Tanner M, Isola J, Mertens F, and Wennerberg
J: Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in
squamous cell carcinoma of the head and neck. Int J Oncol 2002; 20(1): 45-52.
4
5
Submitted
1.
Adeyinka A, Baldetorp B, Mertens F, Olsson H, Johannsson O, Heim S, and Pandis N:
Comparative cytogenetic and DNA flow cytometric analysis of 242 primary breast carcinomas. Submitted.
2.
Brun E, Tennvall J, Baldetorp B, Kjellén E, Fallenius G, and Wennerberg J: S-phase
and DNA ploidy before and during therapy of HNSCC and associations to FDG-PET.
Submitted.
3.
Fredriksson I, Liljegren G, Palm-Sjövall M, Arnesson L-G, Emdin SO, Fornander T,
Lindgren A, Nordgren H, Idvall I, Holmqvist M, Holmberg L, and Frisell J: Risk factors
for local recurrence after breast-conserving surgery – a large case-control study. Submitted.
4.
Glimelius I, Molin D, Amini R-M, Gustavsson A, Glimelius B, and Enblad G: Bulky disease is the most important prognostic factor in Hodgkin´s lymphoma stage 2B. Submitted.
5.
Högberg T, Fredstorp-Lidebring M, Alm P, Baldetorp B, Larsson G, Ottosen C,
Svanberg L, and Lindahl B: Adjuvant radiotherapy is not necessary in the majority of
patients with early endometrial cancer: report on a prospective population-based treatment program including primary surgery and postoperative risk assessment by means
of DNA-ploidy and histopathology. Submitted.
6.
Jerkeman M, Anderson H, Cavallin-Ståhl E, Dictor M, Hagberg H, Kvalöy S, and
Åkerman M: Analysis of bcl-2, p53, Ki-67 and P-glycoprotein as prognostic indicators in
aggressive lymphoma. Submitted,
7.
Johansson M, Fredlund J, Baldetorp B, and Oredsson S: The influence of proliferation
rate on estimated cell kinetic parameters when using bromodeoxyuridine – flow cytometry technique. Submitted.
8.
Kinhult S, Albertsson M, Eskilsson J, and Cwikiel M: Probucol prevents toxic effects of
5-fluorouracil on vascular endothelium. Submitted to Acta Oncol.
9.
Landgren O, Björkholm M, Bossen Konradsen H, Söderquist M, Nilsson B, Gustavsson
A, Axdorf U, Kallin M, and Grimfors G: A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin´s lymphoma. Submitted.
10.
Lilja Å, Smith G, Malmström P, Salford L, Idvall I, and Horstsman V: A psychological
”risk index” in patients with breast cancer. Logistic regression analyses on relations between unfavourable tumour biological prognostic factors and psychological factors.
Submitted to Perceptual and Motor Skills.
11.
Luoma M-L, Hakamies-Blomqvist L, Sjöström J, Pluzanska A, Hultborn R, Mouridsen
H, Bengtsson N-O, Bergh J, Malmström P-O, Valvere V, Tennvall L, and Blomqvist C:
Prognostic value of quality of life scores for time to progression (TTP) and overall survival in advanced breast cancer. Submitted to Eur J Cancer.
12.
Olsson A, Bryngelsson C, Amiri A, Baldetorp B, and Pero R: Anti-proliferative effects of
the N-substituted benzamides, metoclopramide and 3-chloro-procainamide: Induction
of apoptosis and cell differentiation in HL60 cells. Submitted to Leukemia.
6
13.
Rudolph P, Kuhling H, Alm P, Fernö M, Baldetorp B, Olsson H, and Parwaresch R:
Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Submitted.
14.
Smith G, Lilja Å, Malmström P, and Salford L: Creativity and breast cancer. A Study of
premenopausal women. Submitted to Scand J of Psychology.
In manuscript
Andersson-Engels S, Svanberg K, and Svanberg S: Fluorescence diagnostic imaging. Invited paper in preparation.
Baldetorp B, Bendahl P-O, Fernö M, and Stål O. Group NDFC: Improved DNA flow cytometric S-phase reproducibility between 15 laboratories in analysis of breast cancer using generalized guidelines. Manuscript.
Bendahl P-O, Fernö M, Johansson M, and Baldetorp B: Flow cytometry DNA analysis in
breast cancer – intralaboratory reproducibility. Manuscript.
Eker C, Jaramillo E, Andersson-Engels S, Jonas E, Rubio C, Slezak P, and Svanberg K:
Colonic epithelial polyp discrimination in vivo using laser-induced fluorescence. Manuscript.
Gruvberger S, Baldetorp B, Borg Å, and Oredsson S: p53 dependent and independent
checkpoint controls are activated in docetaxel-treated breast cancer cells in culture. Manuscript.
Gustafsson U, Troy P, de Weert M, Andersson-Engels S, Pålsson S, Svanberg S, and
Svanberg K: Intrinsic fluorescence for in vivo demarcation of cervical precancer. Manuscript.
Hedenfalk I, Hegardt C, Oredsson S, Baldetorp B, Borg Å, and Fadeel B: p53-independent
induction of caspase-3-like activity in SK-BR-3 human breast cancer cells. Manuscript.
Håkansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U, and Fioretas T:
Establishment and phenotypic characterization of human U937 cells with inducible P210
BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Manuscript.
Johansson M, Baldetorp B, and Oredsson S: Estimation of potential doubling time of bromodeoxyuridine-labelled cell populations. Manuscript.
Karu I, Pålsson S, Wang I, af Klinteberg C, Bendsoe N, Andersson-Engels S, Svanberg S,
and Svanberg K: Photodynamic therapy using -amino levulinic acid and intensity modulated
diode laser light. Manuscript.
Karu I, Wang I, af Klinteberg C, Andersson-Engels S, Svanberg S, and Svanberg K: Evaluation of pain and dysesthesia in connection with diode laser mediated ALA-PDT. Manuscript.
7
Malmström P, Elston CW, Bendahl P-O, Baldetorp B, Boiesen P, and Fernö M: Histological
grade, its three components and flow cytometric S-Phase as prognostic markers in premenopausal women with node negative breast cancer. Manuscript.
Pålsson S, Gustafsson L, Stenram U, Soto Thompson M, Johansson T, Stenberg M, Andersson-Engels S, Svanberg K, and Svanberg S: Evaluation of the required absorbed light
dose for tumour necrosis due to interstitial photodynamic therapy. Manuscript.
Pålsson S, Stenram U, Jacobson E, McLaughlin B, Andersson-Engels S, Svanberg S, and
Svanberg K: Detailed histopathology correlated to fluorescence spectra and imaging in human cervical tissue. Manuscript.
Pålsson S, Gustafsson U, Stenram U, Soto Thompson M, Johansson T, Andersson-Engels
S, Svanberg K, and Svanberg S: Estimation of the Protoporphyrin IX photodynamic threshold
dose. Manuscript.
Pålsson S, Gustafsson L, Soto Thompson M, Stenberg M, Bendsoe N, Andersson-Engels S,
and Svanberg K: Kinetics of the superficial perfusion and temperature in connection with
photodynamic therapy of basal cell carcinomas using esterified and non-esterified 5aminolevulinic acid. Manuscript.
Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl P-O, Borg Å, Karhu R, Tanner M, Tirkkonen M, and Isola J: Prognostic and clinicopathologic correlations of chromosomal imbalances in breast cancer. A study of 305 tumors by comparative genomic hybridization. Manuscript.
Rydell R, Eker C, Andersson-Engels S, Wahlberg P, and Svanberg K: Fluorescence investigations to identify laryngeal lesions in vivo. Manuscript for Head and Neck.
Soto Thompson M, Johansson T, Pålsson S, Andersson-Engels S, Svanberg S, Bendsoe N,
Stenram U, Svanberg K, Spigulis J, Derjabo A, and Kapostins J: Photodynamic therapy of
basal cell carcinoma with multi-fibre contact light delivery. Manuscript.
Troy P, Jacobson E, McLaughlin B, Andersson-Engels S, Vaitkuviene A, Pålsson S, Soto
Thompson M, Svanberg S, and Svanberg K: Classification of cervical tissue type in vivo by
means of fluorescence point-monitoring and hyperspectral imaging. Manuscript.
de Weert M, Troy P, Gustafsson U, Andersson-Engels S, Pålsson S, Svanberg S, and
Svanberg K: Quantification of context information in hyperspectral fluorescence imaging of
human cervical tissue. Manuscript.
Mars 2003/MF
8